- Home
- AVXL vs XNCR Comparison
AVXL vs XNCR Comparison
Compare AVXL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- XNCR
- Stock Information
- Founded
- AVXL 2004
- XNCR 1997
- Country
- AVXL United States
- XNCR United States
- Employees
- AVXL N/A
- XNCR N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- AVXL Health Care
- XNCR Health Care
- Exchange
- AVXL Nasdaq
- XNCR Nasdaq
- Market Cap
- AVXL 757.9M
- XNCR 625.6M
- IPO Year
- AVXL N/A
- XNCR 2013
- Fundamental
- Price
- AVXL $8.37
- XNCR $8.06
- Analyst Decision
- AVXL Strong Buy
- XNCR Buy
- Analyst Count
- AVXL 2
- XNCR 9
- Target Price
- AVXL $44.00
- XNCR $30.13
- AVG Volume (30 Days)
- AVXL 703.8K
- XNCR 998.0K
- Earning Date
- AVXL 05-13-2025
- XNCR 05-07-2025
- Dividend Yield
- AVXL N/A
- XNCR N/A
- EPS Growth
- AVXL N/A
- XNCR N/A
- EPS
- AVXL N/A
- XNCR N/A
- Revenue
- AVXL N/A
- XNCR $127,228,000.00
- Revenue This Year
- AVXL N/A
- XNCR N/A
- Revenue Next Year
- AVXL N/A
- XNCR $25.05
- P/E Ratio
- AVXL N/A
- XNCR N/A
- Revenue Growth
- AVXL N/A
- XNCR N/A
- 52 Week Low
- AVXL $3.51
- XNCR $7.16
- 52 Week High
- AVXL $14.44
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- AVXL 44.23
- XNCR 36.87
- Support Level
- AVXL $7.98
- XNCR $7.89
- Resistance Level
- AVXL $8.68
- XNCR $8.39
- Average True Range (ATR)
- AVXL 0.41
- XNCR 0.82
- MACD
- AVXL -0.08
- XNCR -0.12
- Stochastic Oscillator
- AVXL 23.31
- XNCR 5.45
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.